Table 1.
Type of study | Deferiprone group |
Deferoxamine group |
p | Outcome/reported outcome variable | |||
---|---|---|---|---|---|---|---|
n | Outcome | n | Outcome | ||||
Clinical parameters | |||||||
Borgna-Pignatti et al. [2006] | Natural history | 157 | 0 | 359 | 0.6–3.4 | <0.001 | No. of cardiac events per calendar year (range) |
Piga et al. [2003] | Retrospective | 54 | 2/54 (4%) | 75 | 15/75 (20%) | 0.007 | Overall ratio of patients with worsening cardiac status |
Laboratory parameters | |||||||
Myocardial T2* (ms) | |||||||
Anderson et al. [2002] | Case control | 15 | 34.0 (18.0–56.0) | 30 | 11.4 (7.0–25.0) | 0.020 | Median (IQR) |
Pennell et al. [2006] | Randomized controlled trial | 29 | 16.5 | 32 | 15.0 | 0.023 | Geometric mean |
Perifanis et al. [2007] | Retrospective | 19 | 35.77 (18.3) | 23 | 23.77 (13.0) | 0.001 | Median (SD) |
Normal range >20 ms | |||||||
Left ventricular ejection fraction (%) | |||||||
Anderson et al. [2002] | Case control | 15 | 70 (6.5) | 30 | 63 (6.9) | 0.004 | Mean (SD) |
Pennell et al. [2006] | Randomized controlled trial | 29 | 72.8(3.6) | 32 | 68.7 (3.4) | 0.003 | Mean (SD) |
Normal range 56–78% |
IQR, interquartile range; SD, standard deviation.